192 related articles for article (PubMed ID: 33108988)
1. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
[TBL] [Abstract][Full Text] [Related]
2. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
4. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody utilization characteristics in patients with multiple myeloma.
Ailawadhi S; Sher T; Azzouqa AG; Meghji Z; Jain T; Jani P; Ahmed S; Diehl N; Roy V; Shah V; Hodge D; Ailawadhi M; Alegria VR; Paulus A; Chanan-Khan A; Fonseca R
Anticancer Drugs; 2019 Sep; 30(8):859-865. PubMed ID: 31415286
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
8. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
[TBL] [Abstract][Full Text] [Related]
9. Safety of ninety-minute daratumumab infusion.
Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
11. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
15. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Bladé J; Luo M; Sun YN; Zhou H; Nnane I; Deraedt W; Qi M; Ukropec J; Clemens PL
Adv Ther; 2020 Apr; 37(4):1464-1478. PubMed ID: 32078124
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Rifkin R; Singer D; Aguilar KM; Baidoo B; Maiese EM
Clin Ther; 2019 May; 41(5):866-881.e7. PubMed ID: 31030993
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
[TBL] [Abstract][Full Text] [Related]
20. Retrospective review of accelerated daratumumab administration.
Patel A; Clark S; Espiritu J; Dechen T; Tran Q
J Oncol Pharm Pract; 2022 Jun; 28(4):816-821. PubMed ID: 33866892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
